Loading...
01/11 11:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite missing EPS expectations, ADMA Biologics showed strong financial performance with significant revenue and income growth. Optimistic guidance and potential billion-dollar opportunities in ASCENIV and SG-001 further bolster sentiment. The Q&A section revealed positive demand trends and operational efficiency improvements, although some management responses lacked clarity. Given the company's small-cap status and strong growth trajectory, the stock is likely to experience a positive price movement over the next two weeks.
Total Revenue Q4 2024 $117.5 million, an increase of 59% year-over-year from $73.9 million in Q4 2023, primarily due to increased sales of ASCENIV.
Total Revenue FY 2024 $426.5 million, an increase of 65% year-over-year from $258.2 million in FY 2023, driven by increased acceptance and utilization of ASCENIV.
Gross Profit FY 2024 $219.6 million, with a gross margin of 51.5%, up from $88.9 million and 34.4% in FY 2023, due to a favorable mix of higher margin IG sales and reduced manufacturing costs.
Adjusted EBITDA Q4 2024 $48.3 million, compared to $18.6 million in Q4 2023, reflecting substantial increases in operating income.
Adjusted EBITDA FY 2024 $164.6 million, an increase of 309% from $40.2 million in FY 2023, primarily due to substantial increases in operating income.
GAAP Net Income Q4 2024 $111.9 million, compared to a net loss of $17.6 million in Q4 2023, due to higher operating income, lower interest expense, and an income tax benefit.
GAAP Net Income FY 2024 $197.7 million, an increase of $225.9 million from a net loss of $28.2 million in FY 2023, driven by higher operating income and lower interest expenses.
Adjusted Net Income Q4 2024 $33.4 million, compared to $8.5 million in Q4 2023, reflecting improved operational performance.
Adjusted Net Income FY 2024 $119.2 million, an increase of $118.5 million from $0.7 million in FY 2023, primarily due to increased operating income.
Total Cash Holdings Exceeding $103 million at year-end 2024, representing a net cash surplus relative to $75 million of total debt, providing a solid foundation for strategic initiatives.
ASCENIV: ASCENIV’s forward-looking demand metrics are making new all-time highs into 2025, resulting in a queue of identified new patients waiting to initiate ASCENIV treatment.
SG-001: SG-001 targeting strep pneumonia represents an additional upside lever to currently provided $1 billion total annual revenue guidance expected to be realized prior to 2030.
Market Penetration: Currently penetrated just over 3% of ASCENIV’s targeted, complex and refractive PI market, with strong visibility into scaling new patient starts.
High-Titer Plasma Supply Contracts: Executed third-party high-titer plasma supply contracts from approximately 250 US-based plasma collection centers, representing a fivefold increase in total collection capacity.
Enhanced Yield Production Process: Anticipated mid-year regulatory approval for enhanced yield production process, potentially increasing production output by approximately 20%.
Financial Guidance: Revised financial guidance upwards, expecting total revenue to exceed $490 million in 2025 and $605 million in 2026.
Long-Term Agreements: Long-term agreements for high-titer plasma supply are expected to sustain ASCENIV’s revenue growth and position the company for potential $1 billion in total annual revenue prior to 2030.
Operational Excellence: Commitment to operational excellence continues to drive strong performance, allowing for upward revisions in financial guidance.
Earnings Expectations: ADMA Biologics missed earnings expectations with a reported EPS of $0.14, below the expected $0.15.
Regulatory Approval: The company anticipates a potential mid-year regulatory approval for its enhanced yield production process, which is crucial for increasing production output.
Supply Chain Challenges: ADMA is ramping up third-party high-titer plasma procurement contracts, which are essential for sustaining ASCENIV’s revenue growth.
Competitive Pressures: The company is focused on expanding its market penetration in the complex and refractive PI market, where it currently holds just over 3%.
Audit Process: The ongoing KPMG audit process may pose risks related to the accuracy and quality of financial statements, although management expresses confidence in the reported financials.
Economic Factors: The current political and economic backdrop may impact the company's operations and financial performance.
Total Revenue Growth: Total revenues reached $426.5 million reflecting an increase of 65% year-over-year.
Adjusted EBITDA Growth: Adjusted EBITDA grew to $164.6 million representing a growth rate of 309% from the previous year.
Revenue Guidance for 2025: Expect total revenue to exceed $490 million in 2025.
Revenue Guidance for 2026: Expect total revenue to reach $605 million in 2026.
Adjusted EBITDA Guidance for 2025: Projected to surpass $225 million in 2025.
Adjusted EBITDA Guidance for 2026: Projected to surpass $305 million in 2026.
Adjusted Net Income Guidance for 2025: Raised to more than $175 million.
Adjusted Net Income Guidance for 2026: Raised to more than $235 million.
ASCENIV Market Opportunity: ASCENIV represents a potential $1 billion or more opportunity with growth expected through at least 2035.
High-Titer Plasma Supply Contracts: Executed contracts with approximately 250 US-based third-party plasma collection centers, increasing collection capacity fivefold.
SG-001 Revenue Potential: If approved, SG-001 could contribute $300 million to $500 million or more in high margin annual revenue.
Cash Position: Total cash holdings exceeded $103 million, representing a net cash surplus relative to $75 million of total debt.
Regulatory Approval Timeline: Anticipated approval of enhanced yield production process by mid-year 2025.
ASCENIV Demand Metrics: ASCENIV’s forward-looking demand metrics are making new all-time highs into 2025.
Long-Term Growth Strategy: Positioned to exceed $1 billion in total annual revenue prior to 2030 with anticipated growth headroom thereafter.
Share Repurchase Program: None
The earnings call summary presents strong financial metrics, including a 10% QoQ revenue increase and significant gross margin expansion. The Q&A reveals optimism about ASCENIV's market potential and raised 2026 guidance, despite some management ambiguity. No negative trends were identified. Given the market cap, a positive stock price movement (2% to 8%) is anticipated due to strong financial performance, optimistic guidance, and strategic growth initiatives.
The earnings call shows strong financial performance with a 14% revenue increase, improved gross margins, and positive cash flow. The company has raised its revenue and EBITDA guidance for 2025 and 2026, indicating optimism. The stock repurchase program is value-accretive. The Q&A highlights strong demand and no margin headwinds, though some uncertainty exists regarding HEOR data. Overall, given the market cap, the positive financial results, and strategic initiatives like yield enhancement, the stock is likely to see a positive reaction in the short term, within the 2% to 8% range.
The earnings call highlights strong financial performance, including 40% revenue growth and improved margins. The stock repurchase program and reduced debt costs further boost investor confidence. While some management responses lacked clarity, the overall sentiment is positive due to the optimistic guidance, successful FDA approval, and robust supply chain improvements. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
Despite missing EPS expectations, ADMA Biologics showed strong financial performance with significant revenue and income growth. Optimistic guidance and potential billion-dollar opportunities in ASCENIV and SG-001 further bolster sentiment. The Q&A section revealed positive demand trends and operational efficiency improvements, although some management responses lacked clarity. Given the company's small-cap status and strong growth trajectory, the stock is likely to experience a positive price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
